Patents by Inventor Thomas P. Markotan

Thomas P. Markotan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE
    Publication number: 20230116771
    Abstract: Provided herein are maytansinoid compounds, derivatives thereof, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.
    Type: Application
    Filed: August 16, 2022
    Publication date: April 13, 2023
    Inventors: Thomas NITTOLI, Thomas P. MARKOTAN
  • Maytansinoid derivatives, conjugates thereof, and methods of use
    Patent number: 11446389
    Abstract: Provided herein are maytansinoid compounds, derivatives thereof, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: September 20, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Thomas Nittoli, Thomas P. Markotan
  • MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE
    Publication number: 20200121806
    Abstract: Provided herein are maytansinoid compounds, derivatives thereof, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.
    Type: Application
    Filed: October 24, 2019
    Publication date: April 23, 2020
    Inventors: Thomas Nittoli, Thomas P. Markotan
  • Amino acid acylation reagents and methods of using the same
    Patent number: 10526344
    Abstract: Provided herein are compounds useful for appending amino acids to nucleophiles.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: January 7, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Thomas Nittoli, Srinath Thirumalai Rajan, Thomas P. Markotan, Nareshkumar Jain
  • Maytansinoid derivatives, conjugates thereof, and methods of use
    Patent number: 10463749
    Abstract: Provided herein are maytansinoid compounds, derivatives thereof, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: November 5, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Thomas Nittoli, Thomas P. Markotan
  • MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE
    Publication number: 20180289834
    Abstract: Provided herein are maytansinoid compounds, derivatives thereof, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.
    Type: Application
    Filed: February 27, 2018
    Publication date: October 11, 2018
    Inventors: Thomas Nittoli, Thomas P. Markotan
  • AMINO ACID ACYLATION REAGENTS AND METHODS OF USING THE SAME
    Publication number: 20180237456
    Abstract: Provided herein are compounds useful for appending amino acids to nucleophiles.
    Type: Application
    Filed: March 17, 2016
    Publication date: August 23, 2018
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Thomas NITTOLI, Srinath Thirumalai RAJAN, Thomas P. MARKOTAN, Nareshkumar JAIN
  • Maytansinoid derivatives, conjugates thereof, and methods of use
    Patent number: 9950076
    Abstract: Provided herein are maytansinoid compounds, derivatives thereof, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: April 24, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Thomas Nittoli, Thomas P. Markotan
  • MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE
    Publication number: 20170209591
    Abstract: Provided herein are maytansinoid compounds, derivatives thereof, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.
    Type: Application
    Filed: January 24, 2017
    Publication date: July 27, 2017
    Inventors: Thomas Nittoli, Thomas P. Markotan
  • Cyclohexyl-azetidinyl antagonists of CCR2
    Patent number: 9062048
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: June 23, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: James C. Lanter, Thomas P. Markotan, Nalin Subasinghe, Zhihua Sui
  • 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2
    Patent number: 8921559
    Abstract: The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, X, Y, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: December 30, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: James C. Lanter, Thomas P. Markotan, Nalin Subasinghe, Zhihua Sui, Xuqing Zhang
  • CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
    Publication number: 20130310365
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: July 22, 2013
    Publication date: November 21, 2013
    Applicant: Janssen Pharmaceutical NV
    Inventors: James C. Lanter, Thomas P. Markotan, Nalin Subasinghe, Zhihua Sui
  • Cyclohexyl-azetidinyl antagonists of CCR2
    Patent number: 8518969
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: August 27, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: James C. Lanter, Thomas P. Markotan, Nalin Subasinghe, Zhihua Sui
  • 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2
    Patent number: 8269015
    Abstract: The present invention comprises compounds of Formula (I). wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: September 18, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Xuqing Zhang, Heather Rae Hufnagel, Chaozhong Cai, James C. Lanter, Thomas P. Markotan, Zhihua Sui
  • 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2
    Publication number: 20120142733
    Abstract: The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, X, Y, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    Type: Application
    Filed: November 30, 2011
    Publication date: June 7, 2012
    Inventors: James C. Lanter, Thomas P. Markotan, Nalin Subasinghe, Zhihua Sui, Xuqing Zhang
  • Triazolopyridazine compounds
    Patent number: 8173654
    Abstract: The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: May 8, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Tianbao Lu, Richard Alexander, Richard W. Connors, Maxwell D. Cummings, Robert A. Galemmo, Heather Rae Hufnagel, Dana L. Johnson, Ehab Khalil, Kristi A. Leonard, Thomas P. Markotan, Anna C. Maroney, Jan L. Sechler, Jeremy M. Travins, Robert W. Tuman
  • CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
    Publication number: 20110312936
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: June 16, 2011
    Publication date: December 22, 2011
    Inventors: James C. Lanter, Thomas P. Markotan, Nalin Subasinghe, Zhihua Sui
  • Triazolopyridazines as kinase modulators
    Patent number: 8030305
    Abstract: The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: October 4, 2011
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Tianbao Lu, Richard Alexander, Richard W. Connors, Maxwell D. Cummings, Robert A. Galemmo, Heather Rae Hufnagel, Dana L. Johnson, Ehab Khalil, Kristi A. Leonard, Thomas P. Markotan, Anna C. Maroney, Jan L. Sechler, Jeremy M. Travins, Robert W. Tuman
  • 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2
    Publication number: 20100267688
    Abstract: The present invention comprises compounds of Formula (I). wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    Type: Application
    Filed: April 15, 2010
    Publication date: October 21, 2010
    Inventors: Xuqing Zhang, Heather Rae Hufnagel, Chaozhong Cai, James C. Lanter, Thomas P. Markotan, Zhihua Sui
  • Acylhydrazones as kinase modulators
    Patent number: 7662824
    Abstract: The invention is directed to acylhydrazones compounds of Formula I: where R1, R2 and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Grant
    Filed: March 16, 2006
    Date of Patent: February 16, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kristi Leonard, Tianbao Lu, Robert W. Tuman, Dana L. Johnson, Anna C. Maroney, Jan L. Sechler, Richard W. Connors, Richard S. Alexander, Maxwell D. Cummings, Robert A. Galemmo, Thomas P. Markotan